Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer

NCT06371482 is registered in ClinicalTrials.gov with Hebei Medical University Fourth Hospital as lead sponsor.

NCT NCT06371482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06371482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer
Lead sponsor
Hebei Medical University Fourth Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2023
Completion date
December 31, 2027
Enrollment
58 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sclc, limited stage